More Than 30 Studies At Lung Cancer Meeting

Lilly To Unveil More Than 30 Studies At Premier Lung Cancer Meeting (PharmaceuticalOnline)
Eli Lilly and Company continues to lead the way in advancing lung cancer treatment. On the heels of new FDA and European Commission approvals for ALIMTA(®) (pemetrexed for injection) as a treatment for nonsquamous non-small cell lung cancer (NSCLC) in the maintenance setting, the company will release findings from more than 30 lung cancer studies at the 13th World Conference on Lung Cancer.